Geospatial Genomics: Operationalizing Multilevel Conceptual Frameworks of Cancer Health Outcomes to Account for Gene-Person-Place Relationships At the time of the primary PFS analysis, interim ...
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study This phase III randomized trial (VIKTORIA-1; ...
RP2D zovegalisib 600 mg BID plus fulvestrant yielded ORR 38.7% (31 evaluable) and tumor reduction in 80.6%, supporting mutant-selective PI3Kα targeting after endocrine resistance. Antitumor activity ...
Piqray plus Faslodex significantly improved PFS in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer after CDK4/6 inhibitor treatment. The EPIK-B5 study reported a median ...
・The decision also marks the FDA’s first approval of a PROTAC therapy, a type of targeted protein-degrading drug. ・The approval is based on a Phase 3 trial, in which Veppanu reduced the risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results